Beruflich Dokumente
Kultur Dokumente
Ralph Downey, III, PhD Staff Sleep Specialist, Cleveland Clinic Foundation; Associate
Clinical Professor of Medicine, Loma Linda University School of Medicine
Ralph Downey, III, PhD is a member of the following medical societies: American Academy
of Sleep Medicine
Practice Essentials
Obstructive sleep apnea (OSA)also referred to as obstructive sleep apnea-hypopneais a
sleep disorder that involves cessation or significant decrease in airflow in the presence of
breathing effort. It is the most common type of sleep-disordered breathing and is
characterized by recurrent episodes of upper airway collapse during sleep.[1] These episodes
are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.
OSA that is associated with excessive daytime sleepiness is commonly called obstructive
sleep apnea syndromealso referred to as obstructive sleep apnea-hypopnea syndrome.
The image below illustrates the sleep-related disordered breathing continuum ranging from
simple snoring to OSA.
Witnessed apneas, which often interrupt the snoring and end with a snort
Gasping and choking sensations that arouse the patient from sleep, though in a very
low proportion relative to the number of apneas they experience
Nocturia
Insomnia; restless sleep, with patients often experiencing frequent arousals and
tossing or turning during the night
Excessive daytime sleepiness that usually begins during quiet activities (eg, reading,
watching television); as the severity worsens, patients begin to feel sleepy during
activities that generally require alertness (eg, school, work, driving)
Daytime fatigue/tiredness
Decreased vigilance
Morning confusion
Gastroesophageal reflux
Hypertension
Diagnosis
In general, the physical examination is normal in patients with OSA, aside from the presence
of obesity (body mass index: >30 kg/m2), an enlarged neck circumference (men: >43 cm [17
in]; women: >37 cm [15 in]), and hypertension.
Evaluate the upper airway in all patients, particularly in nonobese adults with symptoms
consistent with OSA.
Examination findings may include the following:
Abnormal (increased) Mallampati score: Identifies risk for difficult tracheal intubation
Retrognathia or micrognathia
Systemic arterial hypertension: Present in about 50% of obstructive sleep apnea cases
Pulmonary hypertension
Stroke
Metabolic syndrome
Testing
An overnight sleep study, or polysomnography, is required to diagnose OSA.
Routine laboratory tests, however, are usually not helpful in OSA unless a specific indication
is present. Pulmonary function tests are not indicated to make a diagnosis of, or treatment
plan for, OSA alone. The standard indications for such testing apply to all patients, with or
without OSA.
Obtain a thyrotropin test on any patient with possible OSA who has other signs or symptoms
of hypothyroidism, particularly in elderly individuals.
AASM standards and guidelines for diagnostic polysomnography
The American Academy of Sleep Medicine guidelines for the indications and performance of
polysomnography include the following[2] :
Breathing is monitored, including airflow at the nose and mouth (using both a thermal
sensor and a nasal pressure transducer), effort (using inductance plethysmography),
and oxygen saturation
The breathing pattern is analyzed for the presence of apneas and hypopneas (as per
definitions standardized by the American Academy of Sleep Medicine)
Management
Treatment of OSA partly depends on the patients severity of sleep-disordered breathing.
Those with mild apnea have more options, whereas people with moderate to severe apnea
should be treated with nasal continuous positive airway pressure (CPAP).
Conservative therapy and prevention
The following conservative measures may help manage or prevent OSA:
Avoiding alcohol and other sedatives (particularly 4-6 hours before bedtime)
Mechanical measures
Mechanical measures used in the treatment of OSA include the following:
Pharmacotherapy
Medications are generally not a part of the primary treatment recommendations for OSA.
However, central nervous system stimulants such as modafinil and armodafinil have been
used adjunctively in the management of this condition.
Surgery
Surgical intervention for OSA includes, but is not limited to, the following:
Uvulopalatopharyngoplasty
Tracheostomy
Background
Obstructive sleep apnea (OSA)also referred to as obstructive sleep apnea-hypopnea
(OSAH)is a sleep disorder that involves cessation or significant decrease in airflow in the
presence of breathing effort. It is the most common type of sleep-disordered breathing (SDB)
and is characterized by recurrent episodes of upper airway (UA) collapse during sleep.[1]
These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from
sleep.
OSA associated with excessive daytime sleepiness (EDS) is commonly called obstructive
sleep apnea syndrome (OSAS)also referred to as obstructive sleep apnea-hypopnea
syndrome (OSAHS). Despite being a common disease, OSAS is underrecognized by most
primary care physicians in the United States; an estimated 80% of Americans with OSAS are
not diagnosed.[3]
Apnea may occur hundreds of times nightly, 1-2 times per minute, in patients with severe
OSA, and it is often accompanied by wide swings in heart rate, a precipitous decrease in
oxygen saturation, and brief electroencephalographic (EEG) arousals concomitant with
stertorous breathing sounds as a bolus of air is exhaled when the airway reopens.
The cardinal symptoms of sleep apnea include the "3 S s": S noring, S leepiness, and S
ignificant-other report of sleep apnea episodes. This helpful mnemonic has proven to be
valuable in teaching residents to be sensitive in the identification and appropriate referral of
these patients for further study.
Also helpful is if patients spouses or others who are close to them can attend visits. Often,
sleepers are unaware that they have OSA and may in fact regard themselves as "good
sleepers" because they "can sleep anytime, anywhere" (eg, in the physicians waiting room, in
traffic, in class, at his or her office). Sleepiness is one of the potentially most morbid
symptoms of sleep apnea, owing to the accidents that can occur as a result of it.
OSA is a very important diagnosis for physicians to consider because of its strong association
with and potential cause of the most debilitating medical conditions, including hypertension,
cardiovascular disease, coronary artery disease, insulin-resistance diabetes, depression, and,
as mentioned, sleepiness-related accidents.
Go to Childhood Sleep Apnea for complete information on this topic.
For the purposes of the following discussion, it is useful to define the breathing events being
examined. These breathing events include the following:
Apnea
Hypopnea
Apnea is defined by the American Academy of Sleep Medicine (AASM) as the cessation of
airflow for at least 10 seconds.[4] Apnea may last for 30 seconds or even longer.
The most recent guidelines from the American Academy of Sleep Medicine (AASM Weekly
Update 9/26/2013) updated the definitions of the terms for scoring hypopneas (recommended
and acceptable), as follows:
Acceptable: Score a respiratory event as a hypopnea if all of the following criteria are
met: (1) the peak signal excursions drop by 30% or greater of pre-event baseline using
nasal pressure (diagnostic study), positive airway pressure device flow (titration
study), or an alternative hypopnea sensor (diagnostic study); (2) the duration of the at
least 30% drop in signal excursion is 10 or more seconds; and (3) there is 4% or
greater oxygen desaturation from pre-event baseline.
Pathophysiology
Conceptually, the UA is a compliant tube and, therefore, is subject to collapse.[9] OSA is
caused by soft tissue collapse in the pharynx.
Transmural pressure is the difference between intraluminal pressure and the surrounding
tissue pressure. If transmural pressure decreases, the cross-sectional area of the pharynx
decreases. If this pressure passes a critical point, pharyngeal closing pressure is reached.
Exceeding pharyngeal critical pressure (Pcrit) causes a juggernaut of tissues collapsing
inward. The airway is obstructed. Until forces change transmural pressure to a net tissue force
that is less than Pcrit, the airway remains obstructed. OSA duration is equal to the time that
Pcrit is exceeded.
Most patients with OSA demonstrate upper airway obstruction at either the level of the soft
palate (ie, nasopharynx) or the level of the tongue (ie, oropharynx). Research indicates that
both anatomic and neuromuscular factors are important.
Anatomic factors (eg, enlarged tonsils; volume of the tongue, soft tissue, or lateral pharyngeal
walls); length of the soft palate; abnormal positioning of the maxilla and mandible) may each
contribute to a decrease in the cross-sectional area of the upper airway and/or increase the
pressure surrounding the airway, both of which predispose the airway to collapse.[10, 11] Note
that in adults, it is very rare for enlarged tonsils and adenoids to be a cause of OSA.
Removing the enlarged adenoids and tonsils alone rarely is an effective surgical remedy; in
children, about 80% who have have OSA are cured with the removal of enlarged adenoids
and tonsils. There is often a misconception that enlarged adenoids and tonsils may be a
singular cause of OSA in both children and adults, but this is not true.
Neuromuscular activity in the UA, including reflex activity, decreases with sleep, and this
decrease may be more pronounced in patients with OSA.[12, 13, 14] Reduced ventilatory motor
output to upper airway muscles is believed to be the critical initiating event leading to UA
obstruction; this effect is most pronounced in patients with a UA predisposed to collapse for
anatomical reasons.
Central breathing instability is a well-established factor contributing to the development of
central sleep apnea (CSA), particularly in patients with severe congestive heart failure (CHF).
[15, 16, 17]
Evidence also indicates that central breathing instability contributes to the
development of OSAS.
First, evidence of UA obstruction in the absence of ventilatory motor output (central sleep
apnea) has been observed.[18] Second, reduction in pharyngeal dilator activity has been
associated with periodic breathing[19, 20, 21] and hypocapnia in subjects with evidence of
inspiratory flow limitation.[22] Third, men have been shown to be more susceptible to the
development of CSA and less responsive to carbon dioxide than women are,[23] a result
consistent with the greater prevalence of OSAS in men than in women.
An important static factor that has been found is the reduced diameter of the pharyngeal
airway in wakefulness in OSA patients compared with non-OSA patients. In the absence of
craniofacial abnormalities, the soft palate, tongue, parapharyngeal fat pads, and lateral
pharyngeal walls are enlarged in OSA patients versus non-OSA patients.
Dynamic factors include nasal and pharyngeal airway resistance, the Bernoulli effect, and
dynamic adherence.
The Bernoulli effect plays an important dynamic role in OSA pathophysiology. In accordance
with this effect, airflow velocity increases at the site of stricture in the airway. As airway
velocity increases, pressure on the lateral wall decreases. If the transmural closing pressure is
reached, the airway collapses. The Bernoulli effect is exaggerated in areas where the airway
is most compliant. Loads on the pharyngeal walls increase adherence and, hence, increase the
likelihood of collapse.
This effect helps to partially explain why obese patients, and particularly those with fat
deposition in the neck, are most likely to have OSA. Moreover, the cross-sectional area of the
airway in patients with OSA is smaller than that of people without OSA; this difference is due
to the volume of the soft tissue, including the tongue, lateral pharyngeal walls, soft palate,
and parapharyngeal fat pads. In one study, the increased volume of these areas was
independent of sex, age, ethnicity, craniofacial size, and fat deposition surrounding the UA.[10]
Given these principles, it is understandable why the likelihood of OSA is increased among
obese patients, why weight loss decreases the risk of OSA, and why physical examination
helps in predicting the presence of OSA. However, the clinical situation is complex because
of the interplay of known static and dynamic factors and because of unknown factors.
Data do not explain why sex, age, and ethnicity are not evenly distributed across
epidemiologic studies of OSA patients. (See Epidemiology.) Furthermore, data or physical
findings are not helpful for determining with precision who will or will not have OSA and
who can or who cannot be cured with UA surgery.
oxygen reuptake.[24] This occurs when mixed-venous blood with depleted oxygen saturation
arrives at the lung in time with the apnea phase.
The rapid change in oxygen desaturation occurred after the second apnea in a series of 10
produced; apneas that followed the second apnea did not have accelerated changes when
compared with the second apnea. Isolated apneas did not show rapid changes in oxygen
saturation.
The clinical implications of these findings suggest that the reason why continuous positive
airway pressure (CPAP) and supplemental oxygen may work to ameliorate rapid desaturation
is related to the extent that apneas can remain isolated. This results in a longer ventilatory
phase to allow venous reoxygenation.
It should be kept in mind that the events studied were not obstructive events but were apneas
associated with hypoxemia. They were not terminated by EEG arousals in a natural way to
end an apnea sequence and were not produced in humans. Therefore, this studys clinical
application is associated with several caveats.
Etiology
The etiology of OSA involves both structural and nonstructural factors, including genetic
factors.
Structural factors
Structural factors related to craniofacial bony anatomy that predispose patients with OSA to
pharyngeal collapse during sleep include the following:
Mandibular hypoplasia
Brachycephalic head form - Associated with an increased AHI in whites but not in
African Americans. [27]
Down syndrome
Marfan syndrome
Prader-Willi syndrome
Structural factors related to nasal obstruction that predispose patients with OSA to pharyngeal
collapse during sleep include polyps, septal deviation, tumors, trauma, and stenosis.
Structural factors related to retropalatal obstruction include (1) an elongated, posteriorly
placed palate and uvula and (2) tonsil and adenoid hypertrophy (particularly in children).
Structural factors related to retroglossal obstruction include macroglossia and tumor.
Studies confirm that craniofacial abnormalities are important in the pathogenesis of OSA,
particularly in nonobese patients and children. Moreover, given that different racial groups
are inclined to develop OSA at varying degrees of obesity, clinicians should particularly
consider the possibility of this disorder in the presence of clinically detectable craniofacial
abnormalities.[28, 29]
Previous studies of craniofacial risk factors for OSA have been based predominantly on
cephalometry. However, differences in head form (measured by the cranial index) and facial
form (measured by the facial index) are considered by anthropologists to provide a basis for
structural variation in craniofacial anatomy.
The association of head and facial form with the AHI was assessed in 364 whites and 165
African Americans. Cranial and facial dimensions were measured using anthropometric
calipers, and other data collected included the body mass index (BMI), neck circumference,
and the AHI.
Cranial index and facial index in whites with OSA (AHI 15) differ from those in whites
without OSA (AHI < 5). The cranial index was increased and the facial index decreased in
subjects with OSA. Cranial and facial indices did not differ in African American subjects
based on OSA diagnosis. In whites with OSA, the cranial index was again greater and the
facial index was again smaller than in African Americans. The researchers suggested that the
cranial index may be useful in phenotyping and identifying population subsets with OSA.[27]
Obesity
Male sex
Age
Postmenopausal state
Alcohol use
Sedative use
Smoking
Familial factors also play a role (see below).[30] Families with a high incidence of OSA are
reported. Relatives of patients with SDB have a 2- to 4-fold increased risk of SDB compared
with control subjects.
Other conditions associated with the development of OSA are as follows:
Hypothyroidism
Neurologic syndromes
Stroke
Acromegaly
Environmental exposures
Hypothyroidism is associated with macroglossia and increased soft tissue mass in the
pharyngeal region and thus with an increased risk of SDB. Hypothyroidism is also associated
with myopathy that may contribute to UA dysfunction. Although it has been linked with the
development of OSA, evidence indicates that its prevalence is no higher in patients with OSA
than in the general population. Accordingly, patients with OSA should not be routinely
screened for hypothyroidism, except possibly elderly women.
Neurologic syndromes associated with OSA include postpolio syndrome, muscular
dystrophies, and autonomic failure syndromes such as Shy-Drager syndrome.
The relationship of OSA to cerebrovascular disease is still being determined. Growing
evidence indicates that the prevalence of OSA is increased in patients who have had a stroke.
However, whether OSA is a risk factor for stroke or stroke is a risk factor for developing
OSA remains unclear.
Like hypothyroidism, acromegaly is associated with macroglossia and increased soft tissue
mass in the pharyngeal region and thus with an increased risk of SDB.
Environmental exposures include smoke, environmental irritants or allergens, and alcohol
and hypnotic-sedative medications.
Genetic factors
A study examined 52 candidate genes most likely to influence OSA.[26] The study sample
included 792 African Americans and 694 European Americans, all older than 18 years. An
AHI of 15 or higher was used to define OSA as a clinical entity; the AHI was statistically
used as both a continuous and a dichotomous trait. In the African American subjects, 1,080
single nucleotide polymorphisms (SNPs) were genotypes; in the European Americans, 505
SNPs were genotypes. Statistical analysis controlled for adjusted for age, age-squared, and
sex, with and without BMI.
The study found the following variants in European Americans: C-reactive protein (CRP) and
glial cell line-derived neurotrophic factor (GDNF) were associated with the AHI as both a
longitudinal and a dichotomous trait. CRP findings increased the odds ratio for the risk of
OSA between 1.45 and 2.87; GDNF increased the odds ratio between 1.53 and 3.89-3.92 for
the GDNF gene that looked at risk allele G and GDNF risk allele A, respectively.
The study found the following variant in African Americans with OSA: r9s526240 within
serotonin receptor 2a. Risk allele A increased the odds ratio for risk of obstructive sleep apnea
from 1.45-2.91 using the reported 95% confidence interval.
CRP appears to mediate inflammation; it is thought to be a marker of inflammation. Such
inflammation may increase OSA by increasing mucosal edema and reducing airway caliber.
GDNF influences ventilatory control. It appears to sense oxygen and carbon dioxide at sleep
onset transitions, hence playing a role in CSA. GDNF influences the growth of sensory
afferent neurons of the carotid body, influencing responses to hypoxia. Its role extends to
influencing the growth of neural pathways that are important for normal respiration,
specifically at the A5 nucleus of the ventrolateral pons, a critical area that regulates
respiratory pattern generation.
The role of 5HT2A includes effects on sleep-wake cycles, importantly influencing rapid eye
movement (REM) sleep stage percentage. Medications such as selective serotonin reuptake
inhibitors (SSRIs) that occupy 5HT2A receptors reduce or eliminate REM sleep percent time.
Other mentioned roles include regulation of upper airway dilator muscle through an
excitatory influence on hypoglossal motor output. 5HT2a is involved in appetite regulation,
thus playing a role in obesity, a well-known risk factor for obstructive sleep apnea.
The study used rather strict criteria to identify other candidate genes, and less stringent
criteria identified other possible candidate genes that may influence the risk of OSA.
Epidemiology
SDB is common in the United States. The National Commission on Sleep Disorders Research
estimated that minimal SDB (RDI >5) affects 7-18 million people in the United States and
that relatively severe cases (RDI >15) affect 1.8-4 million people. The prevalence increases
with age. SDB remains undiagnosed in approximately 92% of affected women and 80% of
affected men.
OSA is increasingly prevalent, in both adults and children, in modern society. The estimated
prevalence has been 2% for women and 4% for men.[31, 32] Similar data have been found in an
epidemiologic study from Pennsylvania.[33, 10] More recent research indicates a prevalence of
4% for women and 9% for men. Data from the Wisconsin Cohort Study indicate that the
prevalence of OSA in people aged 30-60 years is 9-24% for men and 4-9% for women.
The prevalence in children is less certain, but the authors sleep center is seeing increasing
numbers of adolescent patients, who are often obese and present similarly to many of their
adult counterparts, with the important exception that they may be sleepy and/or hyperactive.
A 2007 study has suggested that approximately 6% of adolescents have weekly SDB.[34]
International statistics
The prevalence of OSA in non-American populations has only been studied in men and has
been found to be as low as 0.3% (England) and as high as 20-25% (Israel and Australia). The
prevalence of OSA in Australian men is estimated to be 3%.
Three large epidemiologic studies have demonstrated that the prevalence of OSA in women
appears to increase after menopause.[39, 40, 41] In these studies, women on hormone replacement
therapy (HRT) had a prevalence similar to that of premenopausal women. Postmenopausal
women are 3 times more likely to have moderate-to-severe OSA compared with
premenopausal women. Women who are on HRT are half as likely to have OSA compared
with postmenopausal women who are not on HRT.[42]
Premenopausal women with OSAHS tend to be more obese than men with the same severity
of disease. Thin women with symptoms of OSAHS appear to have an increased frequency of
craniofacial abnormalities.
Evidence indicates that women underreport the symptoms of loud snoring and witnessed
apneas, leading to underreferral to sleep centers. This may explain the marked male
predominance (male-to-female ratio of approximately 8:1) in sleep centerbased studies.
Additionally, women have lower AHIs than men, even after correcting for other demographic
factors such as BMI and neck circumference.[43, 44, 45]
Prognosis
The short-term prognosis, in relation to symptoms such as daytime sleepiness and snoring,
ranges from good to excellent with regular use of CPAP. Several studies, including placebocontrolled studies, have shown significant improvement in measures of cognitive function
and general health status (eg, as measured by the Medical Outcome Study Short-Form 36
health survey) after 4-8 weeks of treatment with CPAP. However, studies have not been
performed in a large population or for more than a 4- to 8-week treatment period.
The long-term prognosis is unknown because no randomized treatment studies investigating
the effect of CPAP on preventing the development of cardiovascular sequelae have been
conducted.
Evidence indicates that OSA is not an independent risk factor for the development of
pulmonary hypertension in the absence of other lung disease, as evidenced by the presence of
daytime hypoxemia, hypercapnia, or obstructive airway disease.[56]
A study of 150 newly diagnosed patients with OSA by Baguet determined that left ventricular
diastolic dysfunction is common in these patients and is related to the severity of oxygen
desaturation.[57]
All of the above evidence strongly suggests that OSA is an independent risk factor for the
development of cardiovascular disease and death. However, at this time, no definitive
randomized studies have investigated the effect of CPAP in preventing the potential
cardiovascular risks.
driving is unclear,[67] and no evidence indicates that simulator performance can be used to
predict accident risk in OSA patients.[68]
Evidence indicates that CPAP improves driving performance. At least 2 studies have shown
improvement on a driving simulator after CPAP use.[69, 70] Specifically, in one study, the
number of off-road events decreased from 17.8 to 9 after 1 month of effective CPAP therapy,
but no change was noted after a month of ineffective pressure set at 1 cm water.
In addition, 2 studies have looked at the effect of CPAP on actual motor vehicle accident
rates. George derived crash rates from Department of Motor Vehicle data for 210 patients
with OSA over a 3-year period before and after CPAP therapy; the crash rate was 0.18 while
untreated, but fell to 0.06 with treatment.[71] Findley et al reported no further crashes in a
group of 36 patients with OSA regularly using CPAP therapy.[72] Thus, evidence suggests that
effective treatment of OSA should decrease accident rates.
Despite the elevated risk of crashing, most patients with OSA have not had a crash; therefore,
determining which OSA patients are likely to have an accident, which patients should have
driving restrictions, and how much benefit would accrue from these restrictions is not clear.[73]
No recent evidence-based guidelines are available regarding driving for the average patient
with OSA. The most recent statement on this topic is from 1994.[74]
One approach to this problem outlined in the 1994 statement is the concept of shared
responsibilities. Educating the patient about the risks of driving while sleepy or inattentive is
the physicians responsibility. One suggestion is that the patient acknowledges this education
by signing a statement to that effect. After receiving proper education, the patients
responsibilities are to avoid driving while sleepy and, preferably, to refrain from driving until
starting treatment for OSA.
Physicians should be referred to their individual state or country motor vehicle departments
for local guidelines.
Patient Education
All patients should receive education about sleep and proper sleep hygiene, OSA, and the
risks of driving while sleepy. They also should receive education regarding the role of nasal
CPAP and the importance of daily use, as well as training in the use of CPAP, from a
physician, trained technician, or nurse for at least the first month of therapy. This training
promotes long-term adherence with treatment